Leukemia

FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia (01-14-2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous... Continue Reading

Pass it On: It’s Leukemia National Awareness Month (09-19-2017)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia and 24,400 deaths in 2016. For lymphoma, the ACS estimates... Continue Reading

Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (09-11-2017)

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.  Although the treatment of CLL/SLL has advanced... Continue Reading

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia (09-5-2017)

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for... Continue Reading

FDA Approves First Gene Therapy (09-1-2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering... Continue Reading

FDA Approves First Gene Therapy (09-1-2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering... Continue Reading

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia (08-22-2017)

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children... Continue Reading

FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia (08-10-2017)

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic,... Continue Reading

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL (07-12-2017)

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial  A Biologics License Application (BLA) for this indication is under FDA priority review; if approved, CTL019 could become... Continue Reading

Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia (06-20-2017)

According to early clinical trial results published in the journal Blood, some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy. AML is the most lethal of the blood cancers,... Continue Reading

Next Page »